TrimethylapigeninCAS# 5631-70-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 5631-70-9 | SDF | Download SDF |
| PubChem ID | 79730 | Appearance | White-beige powder |
| Formula | C18H16O5 | M.Wt | 312.32 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Synonyms | 4',5,7-Apigenin trimethyl ether; 4',5,7-Trimethylapigenin | ||
| Solubility | Soluble in methan | ||
| Chemical Name | 5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one | ||
| SMILES | COC1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)OC)OC | ||
| Standard InChIKey | ZXJJBDHPUHUUHD-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C18H16O5/c1-20-12-6-4-11(5-7-12)15-10-14(19)18-16(22-3)8-13(21-2)9-17(18)23-15/h4-10H,1-3H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Trimethyapigenin may be a potential candidate for anti-atrial fibrillation, it can significantly inhibit the atrial potassium currents hKv1.5/I(Kur) and I(KACh). 2. Trimethyapigenin has anti-inflammatory activity, it can moderately inhibit production of TNF-α. ,iNOS mRNA and iNOS protein in a dose-dependent manner. |
| Targets | Potassium Channel | AChR | TNF-α | NO | NOS | ERK | JNK | IkB | MAPK | IKK |
Trimethylapigenin Dilution Calculator
Trimethylapigenin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.2018 mL | 16.0092 mL | 32.0184 mL | 64.0369 mL | 80.0461 mL |
| 5 mM | 0.6404 mL | 3.2018 mL | 6.4037 mL | 12.8074 mL | 16.0092 mL |
| 10 mM | 0.3202 mL | 1.6009 mL | 3.2018 mL | 6.4037 mL | 8.0046 mL |
| 50 mM | 0.064 mL | 0.3202 mL | 0.6404 mL | 1.2807 mL | 1.6009 mL |
| 100 mM | 0.032 mL | 0.1601 mL | 0.3202 mL | 0.6404 mL | 0.8005 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3-(2,4-Dihydroxyphenyl)propionic acid
Catalog No.:BCN5751
CAS No.:5631-68-5
- Fluoxetine HCl
Catalog No.:BCC1191
CAS No.:56296-78-7
- Aloperine
Catalog No.:BCN8466
CAS No.:56293-29-9
- Uncarine C
Catalog No.:BCC8261
CAS No.:5629-60-7
- Anigorufone
Catalog No.:BCN7171
CAS No.:56252-32-5
- 2-O-Methylanigorufone
Catalog No.:BCN7180
CAS No.:56252-05-2
- Hydroxyanigorufone
Catalog No.:BCN7184
CAS No.:56252-02-9
- Cyclo(Leu-Val)
Catalog No.:BCN2436
CAS No.:5625-50-3
- Cyclo(Tyr-Gly)
Catalog No.:BCN2414
CAS No.:5625-49-0
- Porson
Catalog No.:BCN5750
CAS No.:56222-03-8
- Methyl lycernuate A
Catalog No.:BCN5749
CAS No.:56218-46-3
- Torsemide
Catalog No.:BCC4871
CAS No.:56211-40-6
- Kaempferol 3-O-(6''-galloyl)-beta-D-glucopyranoside
Catalog No.:BCN1416
CAS No.:56317-05-6
- 5,6,7,8-Tetramethoxycoumarin
Catalog No.:BCN5752
CAS No.:56317-15-8
- Moracin M
Catalog No.:BCN3292
CAS No.:56317-21-6
- Conocarpan acetate
Catalog No.:BCN7584
CAS No.:56319-04-1
- Hedychenone
Catalog No.:BCN5753
CAS No.:56324-54-0
- Oxybutynin
Catalog No.:BCC3833
CAS No.:5633-20-5
- Capillarisin
Catalog No.:BCN2461
CAS No.:56365-38-9
- Tirotundin
Catalog No.:BCN5754
CAS No.:56377-67-4
- Epirubicin HCl
Catalog No.:BCC1192
CAS No.:56390-09-1
- Netilmicin Sulfate
Catalog No.:BCC4683
CAS No.:56391-57-2
- Metoprolol Tartrate
Catalog No.:BCC4330
CAS No.:56392-17-7
- UK-5099
Catalog No.:BCC2021
CAS No.:56396-35-1
Suppressive effects of methoxyflavonoids isolated from Kaempferia parviflora on inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells.[Pubmed:21251970]
J Ethnopharmacol. 2011 Jul 14;136(3):488-95.
ETHNOPHARMACOLOGICAL RELEVANCE: The rhizomes of Kaempferia parviflora Wall. ex Baker have been traditionally used in Thailand to treat abscesses, gout, and peptic ulcers. AIM: Previously, we reported that the chloroform fraction of a Kaempferia parviflora extract had an inhibitory effect on rat paw-edema. In the present study, we isolated the constituents of this fraction and investigated the anti-inflammatory mechanism against nitric oxide (NO) production, tumor necrosis factor-alpha (TNF-alpha) and the expression of inducible nitric oxide synthase (iNOS) as well as phosphorylated extracellular signal-regulated kinase (p-ERK), and phosphorylated c-Jun N-terminal kinase (p-JNK). In addition, effects of Trimethylapigenin (4) on the enzyme activities of protein kinases possibly leading to iNOS expression were examined to clarify the targets. MATERIALS AND METHODS: The chloroform fraction was isolated using silica gel column chromatography and HPLC. Isolated compounds were tested against NO and TNF-alpha using RAW264.7 cells. Cytotoxicity and iNOS, p-ERK and p-JNK expression were also examined. RESULTS: Three active components, 5,7-dimethoxyflavone (2), Trimethylapigenin (4), and tetramethylluteolin (5), markedly inhibited the production of NO in lipopolysaccharide (LPS)-activated RAW264.7 cells. Compounds 2, 4, and 5 moderately inhibited production of TNF-alpha. Compounds 2, 4, and 5 strongly inhibited expression of iNOS mRNA and iNOS protein in a dose-dependent manner, but did not inhibit p-ERK or p-JNK protein expression. The most active compound, 4, did not inhibit the enzyme activity of inhibitor of kappaB kinases or mitogen-activated protein kinases, but inhibited that of spleen tyrosine kinase (SYK). CONCLUSION: The mechanism responsible for the anti-inflammatory activity of methoxyflavonoids from the chloroform fraction of the rhizomes of Kaempferia parviflora is mainly the inhibition of iNOS expression, and the inhibition of SYK by 4 may be involved in the suppression of LPS-induced signaling in macrophages.
Effects of the natural flavone trimethylapigenin on cardiac potassium currents.[Pubmed:22583923]
Biochem Pharmacol. 2012 Aug 15;84(4):498-506.
The natural flavones and polymethylflavone have been reported to have cardiovascular protective effects. In the present study, we determined whether quecertin, apigenin and their methylated compounds (3,7,3',4'-tetramethylquecertin, 3,5,7,3',4'-pentamethylquecertin, 7,4'-dimethylapigenin, and 5,7,4'-Trimethylapigenin) would block the atrial specific potassium channel hKv1.5 using a whole-cell patch voltage-clamp technique. We found that only Trimethylapigenin showed a strong inhibitory effect on hKv1.5 channel current. This compound suppressed hKv1.5 current in HEK 293 cell line (IC(5)(0)=6.4 muM), and the ultra-rapid delayed rectify K(+) current I(Kur) in human atrial myocytes (IC(5)(0)=8.0 muM) by binding to the open channels and showed a use- and frequency-dependent manner. In addition, Trimethylapigenin decreased transient outward potassium current (I(to)) in human atrial myocytes, inhibited acetylcholine-activated K(+) current (IC(5)(0)=6.8muM) in rat atrial myocytes. Interestingly, Trimethylapigenin had a weak inhibition of hERG channel current. Our results indicate that trimethyapigenin significantly inhibits the atrial potassium currents hKv1.5/I(Kur) and I(KACh), which suggests that Trimethylapigenin may be a potential candidate for anti-atrial fibrillation.
